How to Reconstitute CJC-1295: Step-by-Step Reconstitution Guide

What Is CJC-1295 and Why Does Reconstitution Matter?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates the anterior pituitary to secrete endogenous growth hormone. The drug-affinity complex (DAC) version carries a lysine-maleimide linker that binds albumin, extending the half-life to approximately 6 to 8 days compared with roughly 30 minutes for native GHRH [1]. The non-DAC form (also marketed as modified GRF 1-29) has a shorter half-life of 30 to 60 minutes and requires more frequent dosing.

Reconstitution is a sterile compounding step. If the technique is poor, particulate contamination, bacterial growth, or peptide degradation can compromise both safety and efficacy. The FDA's guidance on compounding sterile preparations sets the regulatory context: preparations must meet sterility, pyrogen, and potency standards [2].

Why Lyophilized Powder Needs a Diluent

Manufacturers lyophilize peptides to remove water and slow oxidation and hydrolysis, the two dominant degradation pathways for polypeptide chains [3]. Until reconstituted, CJC-1295 powder is stable at room temperature for short periods but is best kept refrigerated or frozen before use.

Bacteriostatic Water vs. Other Diluents

Bacteriostatic water for injection (BWI) contains 0.9% benzyl alcohol as a preservative. This inhibits microbial growth for up to 28 to 30 days after the vial is first punctured, making it the standard diluent for multi-dose peptide vials [4]. Sterile water for injection (SWFI) carries no preservative; once opened, it should be discarded within 24 hours per USP Chapter <797> guidance [5]. Normal saline (0.9% NaCl) is acceptable but can cause mild stinging on injection. BWI is the preferred choice for CJC-1295.

Supplies You Need Before You Start

Gather every item before touching the vials. Fumbling for a missed supply mid-procedure increases contamination risk.

Required Items

• CJC-1295 lyophilized powder vial (2 mg or 5 mg)
• Bacteriostatic water for injection, 30 mL multi-dose vial
• Two 1 mL insulin syringes (28 to 31 gauge, 0.5-inch needle), one for drawing BWI, one for injection
• Alcohol swabs (70% isopropyl alcohol)
• Clean flat surface or sterile field (a fresh paper towel works)
• Permanent marker for labeling
• Sharps container

Optional but Recommended

• Nitrile gloves
• Second pair of eyes for dose verification

Peptide needles in the 28 to 31 gauge range minimize tissue trauma and discomfort at the injection site [6]. Avoid 25-gauge or larger needles for subcutaneous peptide administration.

Step-by-Step CJC-1295 Reconstitution

Step 1: Wash Your Hands

Wash hands thoroughly with soap and water for at least 20 seconds. The CDC confirms handwashing is the single most effective step to reduce healthcare-associated infection [7]. Dry with a clean towel. Optionally don nitrile gloves.

Step 2: Prepare Your Work Surface

Lay a clean paper towel on a stable, well-lit surface. Place your CJC-1295 vial, BWI vial, syringes, and alcohol swabs on it. Do not reconstitute over a sink or near a fan.

Step 3: Swab Both Vial Tops

Using a fresh alcohol swab each time, wipe the rubber septum of the CJC-1295 vial and the BWI vial in a single outward motion. Let both dry for 30 seconds. Wet alcohol can carry contaminants into the vial [8].

Step 4: Calculate Your Diluent Volume

This is where most errors occur. Use the formula below:

Diluent volume (mL) = Vial mass (mcg) ÷ Desired concentration (mcg/mL)

For a 2 mg (2,000 mcg) vial where you want 200 mcg per 0.1 mL (a concentration of 2,000 mcg/mL):

2,000 mcg ÷ 2,000 mcg/mL = 1.0 mL bacteriostatic water

For a 5 mg (5,000 mcg) vial at the same concentration:

5,000 mcg ÷ 2,000 mcg/mL = 2.5 mL bacteriostatic water

The table below covers the most common vial sizes and target concentrations.

| Vial Size | BWI Added | Resulting Concentration | Dose of 200 mcg Draws | |-----------|-----------|------------------------|-----------------------| | 2 mg | 1.0 mL | 2,000 mcg/mL | 0.10 mL (10 units on U-100 syringe) | | 2 mg | 2.0 mL | 1,000 mcg/mL | 0.20 mL (20 units) | | 5 mg | 2.5 mL | 2,000 mcg/mL | 0.10 mL (10 units) | | 5 mg | 5.0 mL | 1,000 mcg/mL | 0.20 mL (20 units) |

A U-100 insulin syringe delivers 1 unit = 0.01 mL. At 2,000 mcg/mL, each unit on the syringe equals 20 mcg, making dose adjustments easy [9].

Step 5: Draw the Bacteriostatic Water

Insert the insulin syringe needle into the BWI vial septum at a 45-degree angle. Invert the vial. Pull the plunger back slowly to your calculated volume. Check for air bubbles; if present, tap the barrel lightly and expel them before withdrawing the needle.

Step 6: Inject BWI Into the CJC-1295 Vial

Hold the CJC-1295 vial upright. Insert the needle at a 45-degree angle and aim the stream of BWI at the inner glass wall of the vial, not directly onto the powder cake. Slow, wall-directed injection preserves peptide structure [10]. Inject the full calculated volume over 10 to 15 seconds.

Step 7: Swirl, Do Not Shake

Remove the needle, cap it, and set the syringe aside. Gently swirl the vial between your fingers using a slow circular motion for 15 to 20 seconds. The solution should become clear and colorless. If you see cloudiness, particulates, or color other than clear-to-slightly-yellow, discard the vial [11].

Shaking a peptide solution introduces air bubbles and can promote aggregation, which reduces bioavailability and may trigger injection-site reactions [12].

Step 8: Inspect the Solution

Hold the vial up to a light source and tilt it slowly. Look for:

• Floating particles (discard)
• Cloudiness or milky appearance (discard)
• Color change to brown or orange (discard)
• Undissolved powder after 2 minutes of swirling (allow 5 more minutes, then discard if still present)

A properly reconstituted CJC-1295 solution is clear and essentially colorless [13].

Step 9: Label the Vial

Write on the vial or a label:

• Date and time of reconstitution
• Concentration (e.g., 2,000 mcg/mL)
• Your initials or patient ID
• Expiration date (28 days from today)

USP <797> requires beyond-use dating for all compounded sterile preparations [5].

Step 10: Store Correctly

Place the labeled vial in the refrigerator at 2 to 8 °C (36 to 46 °F) immediately. Do not freeze a reconstituted peptide solution. Freezing can cause ice-crystal formation that denatures the protein structure [14]. Stability data for reconstituted GHRH-analog peptides support a 28-day refrigerated beyond-use date when stored in BWI [15].

CJC-1295 Dosing Calculator and Common Dose Math

Understanding Units on an Insulin Syringe

U-100 syringes are calibrated assuming 100 units = 1 mL. This means:

• 1 unit = 0.01 mL
• 10 units = 0.10 mL
• 50 units = 0.50 mL

At a concentration of 2,000 mcg/mL, every 10 units drawn = 200 mcg of CJC-1295. This is a common starting dose for growth-hormone-stimulating protocols [16].

Published Dosing Evidence

A Phase 2 study by Teichman et al. (N=65) published in the Journal of Clinical Endocrinology and Metabolism tested CJC-1295 DAC at single subcutaneous doses of 30, 60, 90, or 120 mcg/kg. Doses of 60 mcg/kg and above produced mean GH AUC increases of 2- to 10-fold over baseline that persisted for 6 days [1]. In a multiple-dose arm, 30 or 60 mcg/kg administered once weekly for 8 weeks elevated mean IGF-1 levels by 30 to 50% from baseline (P<0.01) [1].

Based on a 75 kg adult, 60 mcg/kg equals 4,500 mcg per dose. Note that compounded clinical protocols used in telehealth practice typically use lower, more frequent doses (100 to 300 mcg, 2 to 5x weekly) to maintain more physiologic pulsatile GH release [17]. The Endocrine Society's clinical practice guideline on adult growth hormone deficiency underscores the importance of titrating GH therapy to serum IGF-1 levels rather than fixed weight-based dosing [18].

Dose-Frequency Table

| Goal | Typical Dose | Frequency | Weekly Total | |------|-------------|-----------|--------------| | GH pulse augmentation | 100 to 200 mcg | 5x weekly | 500 to 1,000 mcg | | Anti-aging / recovery | 200 to 300 mcg | 3x weekly | 600 to 900 mcg | | Research / clinical trial range | 60 mcg/kg | Once weekly | Varies by weight |

How to Inject CJC-1295 Subcutaneously

Choosing an Injection Site

Subcutaneous injection sites for peptides include the abdomen (2 inches from the navel), the outer thigh, and the flank. Rotate sites with each injection to reduce lipodystrophy risk, a concern documented with repeated subcutaneous injections at fixed sites [19].

Injection Technique

1. Draw your dose using a fresh insulin syringe.
2. Swab the injection site with an alcohol swab and allow 30 seconds to dry.
3. Pinch a fold of skin between thumb and index finger.
4. Insert the needle at 45 degrees (or 90 degrees if skin fold is thick enough).
5. Release the skin fold.
6. Inject slowly over 5 to 10 seconds.
7. Withdraw and apply gentle pressure with a clean swab, do not rub.

The 45-degree approach is recommended for 0.5-inch needles in lean individuals to ensure subcutaneous rather than intramuscular delivery [20].

Timing Relative to Meals and Sleep

GHRH analogs work best when endogenous GH release is highest. Fasting at injection time blunts the somatostatin-mediated suppression of GH, so many protocols recommend injecting CJC-1295 either before bed or at least 2 hours after eating [21]. High-carbohydrate meals raise insulin and suppress GH secretion via somatostatin feedback [22].

Storage, Stability, and Beyond-Use Dating

Lyophilized Powder (Before Reconstitution)

Lyophilized CJC-1295 is stable at room temperature for short shipping periods, but manufacturers typically recommend refrigeration at 2 to 8 °C for storage longer than 2 weeks, or freezing at -20 °C for extended periods up to 12 months. Stability studies on lyophilized GHRH peptides confirm less than 2% degradation over 12 months at -20 °C [23].

Reconstituted Solution

Once BWI is added, the benzyl alcohol preservative inhibits microbial proliferation. USP <797> assigns a Category 2 compounded sterile preparation a beyond-use date of 30 days refrigerated when prepared in a qualifying facility [5]. For home reconstitution, a 28-day beyond-use date is the conservative, widely cited standard [15].

Do not leave reconstituted CJC-1295 at room temperature for more than 30 minutes per use session.

Freeze-Thaw Cycles

Each freeze-thaw cycle applied to a reconstituted solution accelerates peptide aggregation. A study on GH-releasing peptides showed that two freeze-thaw cycles reduced peptide monomer content by 8 to 15% [24]. Avoid freezing the reconstituted vial.

Safety, Side Effects, and Contraindications

Common Adverse Effects

The Teichman et al. Phase 2 trial reported that the most frequent adverse events were injection-site reactions (erythema, pain, and pruritus) occurring in roughly 16% of participants, and transient facial flushing in approximately 8% [1]. Water retention and mild headache appeared in a subset at higher doses.

Contraindications

• Active malignancy (GH can stimulate IGF-1, a known growth factor for certain cancers) [25]
• Untreated hypothyroidism (GH therapy may worsen thyroid function) [18]
• Diabetic retinopathy or uncontrolled diabetes (IGF-1 elevation may worsen retinopathy) [26]
• Pregnancy (no safety data in humans) [27]
• Age <18 without specialist pediatric endocrinology oversight [18]

Drug Interactions

Glucocorticoids blunt GH secretion and can reduce CJC-1295 efficacy [28]. Concurrent use of insulin or insulin secretagogues requires monitoring because IGF-1 elevation has insulin-sensitizing effects that may lower blood glucose [29].

Regulatory and Compounding Context

CJC-1295 is not FDA-approved as a finished drug product. It is available in the United States exclusively through licensed 503A or 503B compounding pharmacies operating under physician prescription [30]. The FDA's 2023 guidance on compounded drug products reinforced that bulk drug substances used in compounding must appear on the 503A bulks list or meet criteria for clinical necessity [31].

The peptide is not a scheduled substance under the DEA Controlled Substances Act, but its legal status as a compounded product means quality control varies by pharmacy. Patients should request a Certificate of Analysis (COA) confirming identity, purity (target ≥98% by HPLC), and endotoxin levels for each lot [32].

Troubleshooting Common Reconstitution Problems

Powder Does Not Dissolve

Allow 10 minutes of gentle swirling. Some lyophilized cakes are denser than others. Gently rolling the vial between your palms for 30 seconds (never shaking) usually resolves incomplete dissolution. If powder remains visible at 15 minutes, the batch may be degraded or the diluent volume may be too low.

Solution Appears Cloudy

Cloudiness indicates peptide aggregation or microbial contamination. Discard the vial. Do not inject a cloudy peptide solution [11].

Syringe Has Air Bubbles

Tap the barrel firmly with your finger while holding the syringe needle-up. Bubbles rise; expel them slowly through the needle before injecting. A small air bubble in a subcutaneous injection is not medically dangerous but can cause mild stinging.

Vial Pressure

If plunger resistance makes drawing difficult, allow negative pressure by inserting the needle and pulling the plunger back before inverting the vial. Alternatively, inject a small air bubble (0.1 mL) into the vial first to equalize pressure.